Nine drugs, including HRS-4642 injection, received approval notices for clinical trials.
November 18, 2025
Source: drugdu
72
Nanfang Finance News, November 17th - Jiangsu Hengrui Medicine Co., Ltd. ( 01276.HK) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Hengrui Medicine Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd., recently received approvals from the National Medical Products Administration for HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, adebecilimab injection, bevacizumab injection, SHR-A2102 for injection, and apple .The Clinical Trial Approval Notices for Famitinib Malate Capsules and Dalcilide Ethylhex ...
https://finance.eastmoney.com/a/202511173566406150.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
